Binds A Hematopoietic Cell Or Component Or Product Thereof (e.g., Erythrocyte, Granulocyte, Macrophage, Monocyte, Platelet, Myelogenous Leukemia Cell, Bone Marrow Stem Cell, Granulocytic Cell Surface Antigen, Hemoglobin, Thrombospondin, Glycophorin, Etc.) Patents (Class 435/343)
-
Patent number: 11407991Abstract: Methods for extracting high quality nucleic acids from a heterogenous collection of nucleic acid-containing materials from a biological sample are disclosed. The heterogenous collection of nucleic-acid containing materials may contain cells or microvesicles, or both. The extractions obtained by the methods described herein are characterized by high yield and high integrity, making the extracted nucleic acids useful for various applications in which high quality nucleic acid extractions are preferred, e.g., a diagnosis, prognosis, or therapy evaluation for a medical condition.Type: GrantFiled: April 26, 2016Date of Patent: August 9, 2022Assignee: Exosome Diagnostics, Inc.Inventors: Wayne Comper, Leileata M. Russo, Johan Karl Olov Skog
-
Patent number: 11104718Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: GrantFiled: November 14, 2017Date of Patent: August 31, 2021Assignee: Bayer HealthCare LLCInventors: Alan Brooks, Richard Feldman, Jian-Ming Gu, Shaun Lippow, Shujun Yuan, Peter Bringmann
-
Patent number: 8981072Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: December 10, 2013Date of Patent: March 17, 2015Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Patent number: 8957193Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: June 5, 2014Date of Patent: February 17, 2015Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140322235Abstract: The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.Type: ApplicationFiled: December 14, 2011Publication date: October 30, 2014Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), INSTITUT PAOLI-CALMETTES, UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille IIInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Patent number: 8865479Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 16, 2010Date of Patent: October 21, 2014Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8835188Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8835187Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8808701Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: December 19, 2012Date of Patent: August 19, 2014Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Patent number: 8772049Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: July 8, 2014Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Publication number: 20140162357Abstract: This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner.Type: ApplicationFiled: September 4, 2013Publication date: June 12, 2014Applicant: NATIONAL JEWISH HEALTHInventors: Yosef Refaeli, Brian C. Turner
-
Publication number: 20140065146Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: September 30, 2013Publication date: March 6, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20140004037Abstract: The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.Type: ApplicationFiled: January 19, 2012Publication date: January 2, 2014Applicant: Therapeutic Proteins, Inc.Inventor: Rosemarie Wilton
-
Patent number: 8546331Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.Type: GrantFiled: July 10, 2012Date of Patent: October 1, 2013Assignee: XBiotech, Inc.Inventor: John Simard
-
Publication number: 20130230540Abstract: The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain.Type: ApplicationFiled: July 10, 2012Publication date: September 5, 2013Applicant: Domantis LimitedInventors: Steven Holmes, Carrie Enever, Steven Grant, David Sansom
-
Patent number: 8481313Abstract: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.Type: GrantFiled: April 22, 2009Date of Patent: July 9, 2013Assignee: Regenerative Research FoundationInventors: Sally Temple, Jeffrey Stern, Enrique L. Salero-Coca
-
Patent number: 8404241Abstract: The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.Type: GrantFiled: March 5, 2010Date of Patent: March 26, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christine Gaucher, Sylvie Jorieux, Christophe De Romeuf
-
Patent number: 8361468Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: August 20, 2012Date of Patent: January 29, 2013Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Patent number: 8323652Abstract: This application relates to agents capable of specifically recognizing GPIb?, a key receptor required for platelet adhesion and aggregation. More specifically, this application relates to monoclonal antibodies and derivatives thereof capable of specifically recognizing both the murine and the human GPIb?. These monoclonal antibodies and derivatives are particularly useful in the treatment or prevention of thrombosis as well as research tools.Type: GrantFiled: November 13, 2009Date of Patent: December 4, 2012Assignee: Canadian Blood ServicesInventors: Heyu Ni, Guangheng Zhu
-
Patent number: 8287853Abstract: Stem cells obtained through in vitro culture with heparan sulphate are described.Type: GrantFiled: August 8, 2008Date of Patent: October 16, 2012Assignee: Agency for Science, Technology and ResearchInventors: Simon McKenzie Cool, Victor Nurcombe
-
Patent number: 8242074Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.Type: GrantFiled: September 14, 2009Date of Patent: August 14, 2012Assignee: XBiotech, Inc.Inventor: John Simard
-
Publication number: 20120135003Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: November 22, 2011Publication date: May 31, 2012Applicant: SBI Biotech, Ltd.Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Patent number: 8178085Abstract: The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality.Type: GrantFiled: February 13, 2006Date of Patent: May 15, 2012Assignee: Agency for Science, Technology and ResearchInventors: Victor Nurcombe, Simon Cool
-
Publication number: 20120027769Abstract: Anti-RhD monoclonal antibodies and methods for the production thereof.Type: ApplicationFiled: December 24, 2009Publication date: February 2, 2012Inventors: Gautam Vinod Daftary, John Kaundinya, Tomas Cinek
-
Patent number: 8048855Abstract: A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD can be suppressed by administering human G-CSF to a transplantation recipient after peripheral blood stem cells transplantation.Type: GrantFiled: October 20, 2000Date of Patent: November 1, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Motoyuki Kataoka, Kaname Yamamoto
-
Publication number: 20110217695Abstract: The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.Type: ApplicationFiled: November 12, 2009Publication date: September 8, 2011Applicant: Schering CorporationInventor: Deba P. Saha
-
Patent number: 8008073Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.Type: GrantFiled: September 2, 2010Date of Patent: August 30, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
-
Patent number: 7915041Abstract: A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1.Type: GrantFiled: June 30, 2005Date of Patent: March 29, 2011Assignee: Seikagaku CorporationInventors: Yoshiyuki Adachi, Naohito Ohno
-
Patent number: 7915004Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.Type: GrantFiled: April 27, 2005Date of Patent: March 29, 2011Assignee: Farma Development S.r.l.Inventors: Alberto Mantovani, Giuseppe Peri
-
Publication number: 20110039300Abstract: The present invention concerns antibodies with enhanced antibody-dependent cell mediated cytotoxicity (ADCC) and method for preparation thereof.Type: ApplicationFiled: August 6, 2010Publication date: February 17, 2011Inventors: ROBERT BAYER, Amy Shen, Reed J. Harris, Domingos Ng
-
Patent number: 7842513Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.Type: GrantFiled: May 2, 2003Date of Patent: November 30, 2010Assignees: AspenBio Pharma, Inc., University of WyomingInventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin
-
Patent number: 7829092Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: December 18, 2008Date of Patent: November 9, 2010Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 7820807Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.Type: GrantFiled: April 8, 2009Date of Patent: October 26, 2010Assignee: Pangenetics BVInventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simons
-
Patent number: 7816500Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.Type: GrantFiled: April 14, 2009Date of Patent: October 19, 2010Inventor: Robert Sackstein
-
Patent number: 7795018Abstract: The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+.Type: GrantFiled: March 18, 2004Date of Patent: September 14, 2010Assignee: Keio UniversityInventors: Masataka Kuwana, Hiroaki Kodama
-
Patent number: 7790166Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: GrantFiled: March 17, 2008Date of Patent: September 7, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mark de Boer, Leah B. Conroy
-
Patent number: 7754867Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: June 10, 2009Date of Patent: July 13, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: 7741114Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14 Aug. 2002, and DSM ACC2551, on 12 Jul. 2002.Type: GrantFiled: March 10, 2009Date of Patent: June 22, 2010Assignee: Hoffmann-La Roche, Inc.Inventors: Hans-Joerg Buehring, Reiner Lammers, Selim Kuci, Tim Conze
-
Patent number: 7731966Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.Type: GrantFiled: April 11, 2008Date of Patent: June 8, 2010Assignee: Canadian Blood ServicesInventors: Heyu Ni, Guangheng Zhu
-
Patent number: 7718780Abstract: The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.Type: GrantFiled: March 31, 2006Date of Patent: May 18, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Jae Wha Kim, Hee Gu Lee, Jong Seok Lim, Seung Chul Choi, Mi Young Cho, Kyoung Eun Baek, Jin Sook Kim, Jong Tae Kim, Do Young Yoon, Dur Han Kwon, Mi-Young Park, Young Il Yeom, Yong-Kyung Choe, Young-Jun Kim
-
Patent number: 7714107Abstract: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.Type: GrantFiled: July 26, 2005Date of Patent: May 11, 2010Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Patent number: 7708977Abstract: A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.Type: GrantFiled: November 12, 2003Date of Patent: May 4, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Toren Finkel, Jonathan M. Hill, Arshed A. Quyyumi
-
Patent number: 7626012Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 22, 2008Date of Patent: December 1, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7618633Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 25, 2007Date of Patent: November 17, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7576188Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.Type: GrantFiled: March 12, 2004Date of Patent: August 18, 2009Assignee: Pharma Mar, S.A.U.Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, José Jimeno, Glynn Thomas Faircloth
-
Patent number: 7547438Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.Type: GrantFiled: December 20, 2006Date of Patent: June 16, 2009Assignee: Pangenetics BVInventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simone
-
Patent number: 7537763Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.Type: GrantFiled: December 5, 2006Date of Patent: May 26, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Toshifumi Mikayama, Hitoshi Yoshida, Walker R. Force, Xingjie Chen, Nobuaki Takahashi
-
Patent number: 7445780Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: August 31, 2007Date of Patent: November 4, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7361345Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: GrantFiled: February 7, 2005Date of Patent: April 22, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mark de Boer, Leah B. Conroy
-
Patent number: RE44359Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: May 15, 2012Date of Patent: July 9, 2013Assignee: Hoffmann-La Roche IncInventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt